An interventional study of Hepatology Home Hospital in Cirrhosis, End Stage Liver DIsease and Liver Cirrhosis, sponsored by Massachusetts General Hospital. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Health services research
This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.
3,255 studies on the registry are indexed under Fibrosis; 465 are open to participants now.
This study's planned enrollment of 30 is below the median of 50 across 2,130 interventional studies indexed under Fibrosis.
Browse Fibrosis studies →Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Patients must have one of the following:
Exclusion Criteria: All existing MGB home hospital criteria apply, with the following taking precedent for this specific condition
Patients with advanced liver disease receive hospital-level care in the home setting
Behavioral: Hepatology Home Hospital
The Hepatology Home Hospital intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with hepatology clinicians regarding care delivered at home to ensure continuity of care.
Escalation Rate
The intervention will be deemed feasible if less than 20% of enrolled patients have escalation of care back to the inpatient (brick-and-mortar) hospital
Time frame: 18 months
Patient Experience
To assess patient experience scores (Picker Patient Experience Questionnaire, Global satisfaction questionnaire) at discharge from HepHospital
Time frame: Up to 90 days
Adverse Event Reporting
We will assess rates of adverse events (acute kidney injury, falls, delirium, deep vein thrombosis/pulmonary embolism, escalation of care back to an inpatient hospital setting for at least 1 overnight stay, and death) for patient enrolled in HepHospital
Time frame: Up to 90 days
Acceptability
Qualitative acceptability ratings from patients, caregivers, and clinicians obtained via exit individual interviews regarding acceptability (i.e. usefulness, effectiveness, and relevance of the intervention) from patients, family caregivers, and clinicians.
Time frame: 18 months
Decline Rate
We will assess rates that patients decline to enroll in HepHospital
Time frame: 18 months
Quality of life (PROMIS-29 +2)
Change in participants' QOL as measured by the PROMIS-29+2 scale throughout the study.
Time frame: Baseline to post-discharge (+5 business day window) and 30-days (+10 business day window) post-discharge
Change in symptom Burden (Edmonton Symptom Assessment System-revised, ESAS-r)
Change in participants' symptom burden as measured by the ESAS-r throughout the study.
Time frame: Baseline to post-discharge (+5 business day window) and 30-days (+10 business day window) post-discharge
Unplanned readmission(s) after index hospitalization
We will assess # of unplanned readmission(s) at 30- and 90-days post-discharge
Time frame: Day of discharge to 30-days and 90-days post-discharge
Emergency Department Visit(s) after index hospitalization
We will assess # of emergency department visit(s) at 30- and 90-days post-discharge
Time frame: Day of discharge to 30-days and 90-days post-discharge
Total costs of care
To assess total costs of the acute care episode
Time frame: 18 months
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital